Allergan builds case for first drug therapy for presbyopiaIf you are in middle aged and find you have to hold your phone at arm’s length to Share XAllergan builds case for first drug therapy for presbyopiahttps://pharmaphorum.com/news/allergen-builds-case-for-first-drug-therapy-for-presbyopia/
Novartis eyes New Year verdict from FDA on delayed LeqvioNovartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by Share XNovartis eyes New Year verdict from FDA on delayed Leqviohttps://pharmaphorum.com/news/novartis-eyes-new-year-verdict-from-fda-on-delayed-leqvio/
Crowdsourced science refines AI prediction of clinical trial outcomesThink of the R&D dollars that could be saved if artificial intelligence (AI) modelling could tell you at Share XCrowdsourced science refines AI prediction of clinical trial outcomeshttps://pharmaphorum.com/news/crowdsourced-science-refines-ai-prediction-of-clinical-trial-outcomes/
Boehringer, Lilly hail Jardiance data in hard-to-treat heart failureBoehringer Ingelheim and Eli Lilly have the results they were hoping for in a large-scale study of Jardiance Share XBoehringer, Lilly hail Jardiance data in hard-to-treat heart failurehttps://pharmaphorum.com/news/boehringer-lilly-hail-jardiance-data-in-hard-to-treat-heart-failure/
Novartis tries to rescue stalled inclisiran filing with FDANovartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on Share XNovartis tries to rescue stalled inclisiran filing with FDAhttps://pharmaphorum.com/news/novartis-tries-to-rescue-stalled-inclisiran-filing-with-fda/
Roche eyes October decision by FDA for wet AMD implantThe FDA has started a review of a new implant version of Roche’s ranibizumab therapy for wet age-related Share XRoche eyes October decision by FDA for wet AMD implanthttps://pharmaphorum.com/news/roche-eyes-october-decision-by-fda-for-wet-amd-implant/
Novartis, HP team up on digital dengue fever surveillanceNovartis and Hewlett Packard Enterprise (HPE) have agreed to collaborate on the development of digital health technologies, starting Share XNovartis, HP team up on digital dengue fever surveillancehttps://pharmaphorum.com/news/novartis-hp-team-up-on-digital-dengue-fever-surveillance/
NICE backs Novartis’ Cosentyx for underdiagnosed back conditionNICE has extended the range of indications that Novartis’ Cosentyx can be prescribed for by the NHS in Share XNICE backs Novartis’ Cosentyx for underdiagnosed back conditionhttps://pharmaphorum.com/news/nice-backs-novartis-cosentyx-for-underdiagnosed-back-condition/
Blueprint’s latest approval for Ayvakit sets up clash with NovartisBlueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM), Share XBlueprint’s latest approval for Ayvakit sets up clash with Novartishttps://pharmaphorum.com/news/blueprints-latest-approval-for-ayvakit-sets-up-clash-with-novartis/
